Better Health for All

Assembly Biosciences is a biotechnology company focused entirely on the research and development of novel therapeutics for serious viral diseases, including chronic hepatitis B and D, and herpesviruses.

These diseases affect millions globally and cause significant mortality. The company does not manufacture or distribute products, focusing solely on R&D, therefore it has no revenue from products with negative health outcomes, and pricing/accessibility data are not applicable. While the company received a $100 million upfront payment from a partnership, there is no specific data on the percentage of Assembly Biosciences' *own* R&D budget allocated to health improvement. The company adheres to Good Clinical Practice (GCP) standards, including informed consent procedures and animal welfare, and conducts randomized, blinded, and placebo-controlled clinical trials. It also offers comprehensive employee benefits, including mental health and wellness programs and an employee assistance program.

Fair Pay & Worker Respect

Assembly Biosciences provides 100% company-covered medical, dental, and vision insurance for employees and their families, with benefits generally effective on the date of hire.

Employee engagement, as indicated by an average Glassdoor rating of 4.1 out of 5 stars (82%) based on 18 reviews, shows 76% of employees would recommend working there and 83% approve of the CEO. There is no public record of substantiated labor-law or human-rights violations in the past three years.

Honest & Fair Business

Assembly Bio has a formal Whistleblowing and Whistleblower Protection Policy, which includes a 24/7 anonymous hotline available to employees, contractors, and third parties, managed by a third-party service provider.

The company explicitly prohibits retaliation against those who report violations in good faith, and allegations of retaliation are promptly investigated. The company reported zero financial restatements for the fiscal year ended December 31, 2024, and indicated no error corrections requiring a recovery analysis of incentive-based compensation. All new employees receive training on anti-bribery and anti-corruption. A globally recognized third-party partner provides external assurance of compliance with ethical standards at least once a year. The company's Form 10-K filing from March 2025 states that Gilead has the right to designate two directors to the company's board of directors.

Kind to Animals

Assembly Biosciences is a biotechnology company focused on research and development, not manufacturing or distributing products. Therefore, KPIs related to product certification, animal agriculture, or animal-derived ingredients are not applicable. The company conducts nonclinical studies, including in vitro and animal studies, for regulatory filings and toxicology, explicitly mentioning studies in non-human primates and GLP toxicology for multiple compounds.

While its policy requires contract research organizations (CROs) to have Institutional Animal Care and Use Committees (IACUC) and practice the 3Rs (Replacement, Reduction, and Refinement), indicating an intent to use non-animal systems whenever possible and minimize animal use, traditional animal assays dominate, particularly where legally mandated for safety profiles. No specific data on the percentage of non-animal methods used or the number of animals used annually is provided, but extensive nonclinical studies are required. The company's R&D expenses for the nine months ended September 30, 2025, were $47.6 million, but there is no explicit mention of the percentage of this budget allocated to animal-free technologies. There is no evidence of participation in multi-stakeholder initiatives for animal-free standards or active engagement in animal welfare policy improvement beyond complying with regulations.

Planet-Friendly Business

Assembly Biosciences, Inc. does not provide specific, quantifiable data for any of the Planet-Friendly Business KPIs in the provided articles. While the company states commitments to environmental, health, and safety (EHS) policies, energy efficiency (e.g., energy-efficient lighting), and resource conservation (e.g., composting and recycling programs), these are general statements of intent or actions without measurable outcomes or percentages that align with the rubric's quantitative thresholds.

External ratings or scores, such as a 'Reduced Green House Gas Emissions: 38.4 score' from a third-party, are not considered company-reported facts for scoring purposes. Therefore, no KPIs can be scored based on the available evidence.

Zero Waste & Sustainable Products

Assembly Biosciences has implemented energy-efficient lighting in its offices and encourages composting and recycling programs.

The company maintains a Chemical Hygiene Plan (CHP) that outlines procedures for hazardous chemical use, storage, monitoring, protective equipment, and disposal, with the CEO responsible for chemical hygiene. The company states compliance with all relevant laws, rules, regulations, and corporate policies.